台股 » 個股 » 生華科 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

生華科

(6492)
可現股當沖
  • 股價
    32.85
  • 漲跌
    ▲0.10
  • 漲幅
    +0.31%
  • 成交量
    65
  • 產業
    上櫃 生技醫療類股
  • 154人加入追蹤

    立即追蹤

  • 本地時間:13:30(已收盤)

     
生華科 (6492)籌碼相關-玉山-數位 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

Created with Highstock 1.3.7Zoom券商分點個股進出嗨投資 histock.tw05/1005/2406/0806/2207/0607/2208/0208/1608/3009/1409/2810/1210/2611/0811/2212/0612/2001/0402/1803/0203/1203/2404/0604/1601/1602/0604/18253035404550May '24Jul '24Sep '24Nov '24Jan '25Mar '2560d90dAll

玉山-數位 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/04/17033.2300.0032.8501730.00%
2025/04/14032.8400.0032.7501800.00%
2025/04/1100.00532.5032.60-5180-2.77%
2025/04/10030.7000.0031.7501790.00%
2025/04/09529.0000.0028.9051772.82%
2025/04/08131.6000.0031.6011650.61%
2025/04/07035.4800.0035.1001530.00%
2025/04/02040.0000.0038.9501570.00%
2025/03/28040.4000.0039.6001570.00%
2025/03/27041.5000.0040.7501510.00%
2025/03/26041.2700.0041.5501490.00%
2025/03/24042.55042.8541.8001490.00%
2025/03/10044.3500.0044.6501480.00%
2025/03/07044.6500.0044.2501480.00%
2025/03/06045.0000.0044.3001490.00%
2025/03/05049.0500.0044.8001500.00%
2025/03/03044.9000.0044.6001530.00%
2025/02/27047.0000.0045.9001520.00%
2025/02/26045.9000.0045.8001500.00%
2025/02/20044.9500.0045.2501480.00%
2025/02/19044.00144.2544.30-1157-0.64%
2025/02/17045.1800.0044.7501620.00%
2025/02/14045.0300.0044.8001630.00%
2025/02/07044.5000.0044.2001860.00%
2025/02/04043.7000.0042.8001980.00%
2025/01/2100.000.142.5042.70-0.1344-0.03%
2024/12/31143.2000.0043.5014100.24%
2024/12/18042.8000.0042.3005150.00%
2024/12/17043.9000.0042.5005730.00%
2024/12/06045.5000.0044.1506110.00%
2024/12/0400.00146.0045.35-1620-0.16%
2024/12/03045.5800.0045.2506290.00%
2024/11/26045.3500.0045.0506600.00%
2024/11/20045.5500.0045.1006820.00%
2024/11/19045.0000.0045.4506880.00%
2024/11/13047.7500.0047.2007190.00%
2024/11/120.147.8000.0047.350.17260.01%
2024/11/06049.5000.0049.3507460.00%
2024/10/29352.83352.6752.1007720.00%
2024/10/28555.58755.3052.60-2756-0.26%
2024/10/25552.72352.4354.4026450.31%
2024/10/23050.0000.0050.0006280.00%
2024/10/2200.00149.3049.60-1646-0.15%
2024/10/21150.00150.0049.9006600.00%
2024/10/18149.8000.0050.0017380.14%
2024/10/17051.80151.8050.50-1850-0.12%
2024/10/16149.8000.0050.6019610.10%
2024/10/0100.00254.6054.20-21,047-0.19%
2024/09/2700.00253.0054.70-21,035-0.19%
2024/09/25053.7000.0053.8001,0180.00%
2024/09/230.655.4500.0054.600.61,0190.06%
2024/09/20254.1000.0055.0021,0230.20%
2024/09/19356.03355.6353.2009950.00%
2024/09/1800.001.250.3852.30-1.2943-0.13%
2024/09/13048.1500.0047.8009670.00%
2024/09/12046.9500.0047.3009790.00%
2024/09/1100.00347.2046.65-31,006-0.30%
2024/09/09249.2800.0048.2021,0340.19%
2024/09/05147.8500.0047.4011,0180.10%
2024/09/04149.5000.0047.8511,0170.10%
2024/09/0300.00151.5051.40-11,007-0.10%
2024/09/02150.3000.0050.7011,0030.10%
2024/08/3000.00151.5051.30-1999-0.10%
2024/08/29150.301.151.4650.00-0.1993-0.01%
2024/08/2800.00250.0550.30-2981-0.21%
2024/08/230.249.1000.0049.350.29660.02%
2024/08/221.149.890.149.7549.8019620.10%
2024/08/20151.00151.2050.9009430.00%
2024/08/190.149.8500.0049.800.19300.01%
2024/08/16149.40150.2050.1009280.00%
2024/08/09048.9500.0048.1508790.00%
2024/08/0600.00550.1049.00-5841-0.59%
2024/07/3000.00155.3056.00-1794-0.13%
2024/07/26052.300.152.7054.50-0.1776-0.01%
2024/07/2300.00255.6054.10-2770-0.26%
2024/07/220.159.7000.0056.200.17520.01%
2024/07/193.559.33459.7858.10-0.5735-0.07%
2024/07/18262.25161.3062.2016580.15%
2024/07/17256.75358.4758.90-1543-0.18%
2024/07/169.256.47757.1057.202.24270.50%
2024/07/0800.00145.4044.70-1315-0.32%
2024/07/05145.3000.0045.6513120.32%
2024/07/0400.00144.6544.85-1310-0.32%
2024/06/2700.00249.0047.10-2296-0.67%
2024/06/26148.851649.3048.75-15288-5.20%
2024/06/25144.4000.0045.2012640.38%
2024/06/24146.1000.0045.5012620.38%
2024/06/21046.7000.0045.2002580.00%
2024/06/17045.0000.0045.3501870.00%
2024/05/1400.000.141.5041.60-0.1179-0.06%
2024/04/1900.00041.4040.7001860.00%
2024/04/18042.2300.0041.9001820.00%
生華科新藥再獲孤兒藥資格 上市可獲7年市場獨賣保護期Anue鉅亨-2024/10/25
上櫃「肥貓」董監現形 台嘉碩、大宇資、穩懋、生華科為前四肥Anue鉅亨-2024/04/15
生華科治療新冠、流感等泛病毒感染新藥 將啟動二期臨床Anue鉅亨-2023/11/21
生華科 相關文章
生華科 相關影音